查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103826

α1-抗胰蛋白酶缺乏症治療市場：全球市場預測，2026-2032年

Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，α-1 抗胰蛋白酶缺乏症治療市場將成長至 67.9 億美元，複合年成長率為 9.78%。

主要市場統計數據
基準年 2025 35.3億美元
預計年份：2026年 38.3億美元
預測年份 2032 67.9億美元
複合年成長率 (%) 9.78%

由於醫療保健系統面臨著與慢性阻塞性肺病(COPD)、肺氣腫、支氣管擴張、肝病以及罕見的脂膜炎相關的遺傳性疾病診斷不足的問題，α1-抗胰蛋白酶缺乏症的治療正變得日益重要。 α1-抗胰蛋白酶缺乏症是由SERPINA1基因的致病性突變引起的，導致血清α1-抗胰蛋白酶水平降低或功能障礙，從而削弱了肺組織對嗜中性白血球彈性蛋白酶損傷的保護作用。目前的治療指引強調早期診斷、戒菸、接種疫苗、肺部復健、使用支氣管擴張劑進行呼吸系統護理、治療急性惡化、監測肝功能，以及對合格的重度缺乏症且確診肺氣腫的成年患者進行靜脈替代治療。隨著血清學檢測、表現型分析、基因分型、家族篩檢、專科轉診網路、居家輸液治療模式以及包括基於RNA和基因標靶策略在內的新型緩解疾病療法的進步，臨床格局也在不斷演變。對相關人員而言，關鍵機會不僅在於治療創新，還在於早期患者篩檢、協調一致的標準化護理以及建立整合呼吸醫學、肝病學、免疫學和遺傳醫學等領域專業知識的循證准入策略。

治療方式的變革性改變。

α1-抗胰蛋白酶缺乏症的治療方法正在重組，從以症狀主導的呼吸系統護理轉向精準診斷和長期疾病管理。傳統上，許多患者在多年進行性性氣流受限後才被確診，但隨著針對不明原因慢性阻塞性肺病（COPD）、早發性肺氣腫、基底肺氣腫、肝功能障礙、組織炎症以及受累個體家族成員的靶向檢測的普及，臨床診斷率顯著提高。治療也從單一介入轉向綜合護理模式，包括肺功能監測、肝功能評估、遺傳諮詢、戒菸指導、疫苗接種、復健以及個人化的替代療法評估。另一個顯著的變化是分散式照護的擴展，包括居家靜脈輸液治療和遠端監測，這可以減輕接受長期治療患者的負擔。科學研究的重點也從蛋白質替代療法轉向旨在減少肝臟中聚合物積聚、增強α1-抗胰蛋白酶活性或在基因和分子層面上改變疾病進展的方法。這些變化提高了人們對更強大的診斷演算法、真實世界數據 (REW) 的創建、與保險公司標準一致的臨床標準以及連接呼吸科醫生、肝病學家、遺傳諮詢師、靜脈輸液治療提供者和基層醫療醫生的多學科治療路徑的期望。

人工智慧（AI）的累積影響

人工智慧 (AI) 正開始影響 α1-抗胰蛋白酶缺乏症的治療，其主要挑戰​​之一是診斷延遲或漏診。 AI 驅動的臨床決策支援系統可以分析電子健康記錄，識別諸如早發性慢性阻塞性肺病 (COPD)、非吸煙者肺氣腫、反覆呼吸道感染疾病、不明原因的肝酶升高、家族病史以及血清 α1-抗胰蛋白酶水平降低等模式，並在必要時提示進行確診性檢查。在影像學領域，機器學習工具可用於支援對肺氣腫分佈和進展的定量評估，從而補充肺功能檢查和臨床評估。 AI 還可以透過整合基因型、表現型、肺功能、影像學、生物標記和治療反應等數據，增強研究中的患者分層，從而識別具有臨床意義的亞群。在醫療服務方面，預測分析可以幫助識別病情加重風險、藥物依從性不足或靜脈輸液方案障礙，而自然語言處理則可以從非結構化的臨床記錄中提取相關觀察。當人工智慧與檢驗的演算法、透明的臨床工作流程、資料隱私保護以及注重公平性（以避免加劇服務不足人口的漏診）相結合時，其累積效應有望最大化。人工智慧不應被視為取代專家解讀或協作式臨床決策，而應被視為一種輔助手段，用於改善病例發現、監測和證據產生。

區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

在亞太地區，α1-抗胰蛋白酶缺乏症的盛行率歷來低於許多西方國家。然而，隨著基因檢測的普及、慢性阻塞性肺病（COPD）表現型分析的改進以及人們對罕見呼吸系統和肝臟疾病認知的提高，該疾病正受到越來越多的臨床關注，尤其是在都市區的專科醫療中心。在北美，相對成熟的診斷和治療系統已建立，這得益於完善的呼吸系統專科醫生網路、基因檢測、增強治療途徑、患者登記系統和家庭輸液治療系統。然而，漏診仍是COPD、氣喘或病因不明肝病患者面臨的一大障礙。在拉丁美洲，確診檢測、專科會診和長期輸液治療的可近性參差不齊，凸顯了針對臨床醫生開展專項培訓、建立集中式檢測設施以及製定重症或早發性COPD轉診方案的必要性。在歐洲，罕見疾病框架更為完善，並具有許多優勢，例如跨境臨床合作、新生兒和家庭篩檢討論以及增強治療合格的既定指南，儘管各國的保險報銷和檢測實踐存在差異。在中東，對三級醫療、遺傳醫學和呼吸系統疾病管理的投入不斷增加，正在改善α1-抗胰蛋白酶缺乏症的檢測基礎設施，尤其是在那些以家庭為基礎的風險評估和國家級基因組舉措支持遺傳疾病識別的地區。在非洲，由於缺乏診斷基礎設施以及與其他醫療保健挑戰的競爭，常規檢測受到限制，但綜合呼吸系統疾病項目、肝病評估、增強檢測能力以及透過遠端醫療建立專家網路可以改善疑似患者的早期發現和持續護理。

區域分析：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協地區，α1-抗胰蛋白酶缺乏症治療的引入與基因檢測能力的提升、呼吸系統醫療設備轉診途徑的完善以及罕見疾病政策的成熟密切相關，發達的都市區醫院與資源匱乏的地區之間存在顯著差異。海灣合作理事會（GCC）國家可以透過投資基因組醫學、建立呼吸專科中心以及在臨床適宜的情況下開展婚前和家庭篩檢模式來促進病例識別，同時確保長期治療方案與國家醫保報銷體系和靜脈輸液服務的可及性相符。歐盟為罕見疾病措施的協調、跨境臨床專業知識的共享、藥物安全監測和循證標準提供了良好的環境，但國家層面的醫保報銷和實施仍然影響著患者的就醫。金磚國家（BRICS）情況複雜多樣，雖然慢性阻塞性肺病（COPD）患者數量龐大、分子診斷技術的普及以及專科醫療體系的健全可能有助於提高檢出率，但經濟負擔、地域可及性和醫療協調仍然是重要的考慮因素。七國集團（G7）國家通常擁有先進的專科醫療、基因診斷、臨床指南、患者權益倡導組織和完善的治療基礎設施，這為評估真實世界數據和下一代療法創造了至關重要的環境。北約成員國的醫療保健系統與北美和歐洲的高所得國家的醫療保健系統高度重合，這些國家的軍民醫療保健系統均可受益於標準化的呼吸系統篩檢方案、職業接觸評估、戒菸計劃以及與遺傳風險相關的慢性肺病的協調管理。

各國主要醫療保健市場的發展趨勢

美國擁有最完善的α1-抗胰蛋白酶缺乏症診療體系之一，專科醫生對該疾病的認知度高，臨床檢測手段完善，可進行確診，並有替代療法和完善的患者支持體系。然而，許多慢性阻塞性肺病（COPD）和肝病患者仍未被確診。加拿大受益於公共醫療合作和呼吸專科醫生網路，但地域分散使得遠端醫療監測和靜脈輸液治療的公平獲取成為必要。墨西哥和巴西有機會透過COPD診所、肝病計畫和家庭篩檢來提高檢出率，但獲得專科診斷和長期治療的機會可能因地區和保險結構而異。英國將罕見疾病領域的專業知識與呼吸系統醫療設備和肝病科服務相結合，以支持系統性診斷和長期監測。另一方面，德國和法國擁有強大的臨床研究能力、專科醫生網路和以指南為基礎的醫療保健系統。俄羅斯、義大利和西班牙在專科醫生資源、社區醫療機構和宣傳活動方面各有不同，因此，建立一致的診斷流程對於及時識別疾病至關重要。在中國和印度，呼吸系統疾病負擔沉重，基因檢測能力正在不斷提升，這為提高不明原因慢性阻塞性肺病（COPD）、支氣管擴張或肝功能異常患者的檢出率提供了巨大潛力。然而，基因檢測的普及程度和臨床醫生的認知程度仍存在差異。在日本、澳洲和韓國，先進的診斷基礎設施和專業的醫療保健體系已經建立，這為完善早期篩檢流程、開展家族篩檢、肝功能監測以及收集真實世界數據（REW）以指導合理的治療方案提供了契機。

為行業領導者提供的實用建議

產業領導者應優先考慮早期診斷，支持對有慢性阻塞性肺病（COPD）、幼年型肺氣腫、基底型肺氣腫、不明原因支氣管擴張、慢性肝病、脂膜炎和α1-抗胰蛋白酶缺乏症家族病史的患者進行符合指南的檢測。醫療模式應整合呼吸科、肝病科、遺傳科、基層醫療、靜脈輸液治療和病患教育，以減少醫療服務片段並支持終身監測。相關人員應投入資源，收集證據以評估臨床結果、治療依從性、生活品質、肺功能進展、急性惡化模式、肝臟相關進展以及居家照護的實際影響。診斷策略應將血清α1-抗胰蛋白酶測定與表現型或基因型鑒定結合，以防止因急性期反應物升高和突變複雜性而導致的漏診。醫療服務取得規劃應解決諸如保險公司標準、靜脈輸液物流、擴大農村地區醫療服務覆蓋範圍、專科轉診延誤和病患負擔等挑戰。包括人工智慧驅動的病例檢測在內的數位化工具，只有在臨床有效性得到檢驗，並採取措施確保隱私、互通性和健康公平性之後，才能引入使用。對於新療法，領導者需要製定教育計劃、生物標記策略、臨床試驗多樣性計劃以及上市後證據構建框架，以反映疾病對肺部和肝臟造成的負擔。

調查方法

本執行摘要基於一套系統化的二手調查方法，重點關注檢驗的臨床、監管、流行病學和科學二手資訊。此方法強調對α1-抗胰蛋白酶缺乏症的遺傳學、診斷、肺部和肝臟症狀、增強療法、監測標準和臨床實驗療法的同行評審文獻。此外，它還納入了來自知名臨床學會、罕見疾病權威機構、公共衛生機構和監管機構的公開指南，以及來自註冊登記、共識聲明和現有真實世界臨床研究的證據。透過資訊來源檢驗法，比較了整個醫療保健系統中的診斷建議、治療合格標準、區域可近性和新興技術趨勢。該調查方法有意排除未經證實的市場規模估算、佔有率分析和預測，而是專注於基於證據的臨床和策略見解。從診斷基礎設施、專家資源、報銷環境、罕見疾病政策、基因檢測成熟度和持續照護能力等方面，分析和解讀了區域、群體和國家的具體情況。

結論

α1-抗胰蛋白酶缺乏症的治療正邁向以精準醫療主導的時代，其特點是早期發現、多學科管理、加強患者支持以及在緩解疾病療法方面取得科學進展。雖然對於某些重度缺乏症和肺氣腫患者而言，增強療法仍然是一種成熟的治療選擇，但更廣泛的治療機會在於識別患者，防止不可逆的肺損傷進展，並確保對肺部和肝臟併發症進行協調監測。區域和國家在診斷、罕見疾病基礎設施和長期治療方面的差異仍然影響著患者的預後。人工智慧、真實世界數據和基因組醫學如果能夠負責任地整合到檢驗的臨床路徑中，可以加速這一進程。最成功的相關人員將是那些將教育、診斷、醫療服務取得、實證醫學和以患者為中心的護理相結合的各方，以減少α1-抗胰蛋白酶缺乏症的漏診，並提高全球治療的品質和一致性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：α1-抗胰蛋白酶缺乏症治療市場：依治療類別分類

  • 輔助性治療
  • 基因治療
    • AAV 載體
    • 慢病毒載體
  • 血漿輸注

第8章：α1-抗胰蛋白酶缺乏症治療市場：依給藥方式分類

  • 吸入
  • 靜脈

第9章：α1-抗胰蛋白酶缺乏症治療市場：依患者年齡層分類

  • 成人
  • 老年人
  • 兒童

第10章：α1-抗胰蛋白酶缺乏症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：α1-抗胰蛋白酶缺乏症治療市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第12章：α1-抗胰蛋白酶缺乏症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：α1-抗胰蛋白酶缺乏症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：α1-抗胰蛋白酶缺乏症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Biotest AG
  • Boehringer Ingelheim International GmbH
  • CSL Behring GmbH
  • GlaxoSmithKline plc
  • Grifols SA
  • Kamada Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals
Product Code: MRR-C002B1C99847

The Alpha 1 Antitrypsin Deficiency Treatment Market is projected to grow by USD 6.79 billion at a CAGR of 9.78% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.53 billion
Estimated Year [2026] USD 3.83 billion
Forecast Year [2032] USD 6.79 billion
CAGR (%) 9.78%

Alpha 1 antitrypsin deficiency treatment is gaining strategic importance as healthcare systems confront the underdiagnosis of a hereditary condition associated with chronic obstructive pulmonary disease, emphysema, bronchiectasis, liver disease, and, in rare cases, panniculitis. Alpha 1 antitrypsin deficiency results from pathogenic variants in the SERPINA1 gene, leading to low circulating alpha 1 antitrypsin levels or dysfunctional protein that inadequately protects lung tissue from neutrophil elastase-mediated damage. Current care pathways emphasize early diagnosis, smoking avoidance, vaccination, pulmonary rehabilitation, bronchodilator-based respiratory management, treatment of exacerbations, liver monitoring, and intravenous augmentation therapy for eligible adults with severe deficiency and established emphysema. The clinical landscape is also evolving through improved serum level testing, phenotyping, genotyping, family screening, specialty referral networks, home infusion models, and emerging disease-modifying approaches, including RNA-based and gene-targeted strategies. For stakeholders, the central opportunity is not only therapeutic innovation but also earlier identification of patients, standardized care coordination, and evidence-led access strategies that align respiratory, hepatology, immunology, and genetic medicine expertise.

Transformative Shifts in the Treatment Landscape

The alpha 1 antitrypsin deficiency treatment landscape is being reshaped by a shift from symptom-led respiratory care toward precision diagnosis and longitudinal disease management. Historically, many patients have been diagnosed only after years of progressive airflow limitation, but broader use of targeted testing in unexplained COPD, early-onset emphysema, basilar emphysema, liver abnormalities, panniculitis, and family members of affected individuals is improving clinical visibility. Treatment is moving beyond episodic intervention toward integrated care models that combine pulmonary function monitoring, liver assessment, genetic counseling, smoking cessation, vaccination, rehabilitation, and individualized augmentation therapy eligibility review. Another major shift is the growth of decentralized care, including home-based infusion support and remote monitoring, which can reduce treatment burden for patients receiving chronic therapy. Scientific attention is also expanding from protein replacement to approaches intended to reduce hepatic polymer accumulation, increase functional alpha 1 antitrypsin activity, or alter disease progression at the genetic and molecular levels. These changes are raising expectations for stronger diagnostic algorithms, real-world evidence generation, payer-aligned clinical criteria, and multidisciplinary treatment pathways that connect pulmonologists, hepatologists, genetic counselors, infusion providers, and primary care clinicians.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence alpha 1 antitrypsin deficiency treatment by addressing one of the field's most persistent challenges: delayed and missed diagnosis. AI-enabled clinical decision support can analyze electronic health records for patterns such as early-onset COPD, emphysema in nonsmokers, recurrent respiratory infections, unexplained liver enzyme elevation, family history, and low serum alpha 1 antitrypsin results, prompting confirmatory testing where appropriate. In imaging, machine learning tools can support quantitative assessment of emphysema distribution and progression, complementing pulmonary function testing and clinical evaluation. AI can also strengthen patient stratification in research by integrating genotype, phenotype, lung function, imaging, biomarker, and treatment-response data to identify clinically meaningful subgroups. For care delivery, predictive analytics may help flag exacerbation risk, adherence gaps, or infusion scheduling barriers, while natural language processing can extract relevant findings from unstructured clinical notes. The cumulative impact is likely to be highest where AI is governed by validated algorithms, transparent clinical workflows, data privacy safeguards, and equity-focused implementation that avoids reinforcing underdiagnosis in underserved populations. AI should be viewed as an assistive layer that improves case-finding, monitoring, and evidence generation rather than as a replacement for specialist interpretation and shared clinical decision-making.

Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

In Asia-Pacific, alpha 1 antitrypsin deficiency has historically been considered less common than in many Western populations; however, expanding genetic testing, improved COPD phenotyping, and greater awareness of rare respiratory and liver diseases are increasing clinical attention, particularly in urban specialty centers. North America demonstrates comparatively mature diagnostic and treatment infrastructure, supported by established respiratory specialty networks, genetic testing availability, augmentation therapy access pathways, patient registries, and home infusion capabilities, although underdiagnosis remains a persistent barrier among individuals labeled with COPD, asthma, or unexplained liver disease. Latin America is characterized by uneven access to confirmatory testing, specialist care, and chronic infusion services, creating opportunities for targeted clinician education, centralized reference laboratories, and referral protocols for severe or early-onset COPD. Europe benefits from stronger rare disease frameworks, cross-border clinical collaboration, selected newborn and family screening discussions, and established guidance for augmentation therapy eligibility, though reimbursement and testing practices differ across countries. In the Middle East, rising investment in tertiary care, genetic medicine, and respiratory disease management is improving the foundation for alpha 1 antitrypsin deficiency detection, especially where family-based risk assessment and national genomic initiatives support inherited disease identification. Across Africa, limited diagnostic infrastructure and competing health priorities constrain routine detection, but integrated respiratory programs, liver disease evaluation, laboratory capacity building, and telemedicine-supported specialist networks can improve recognition and continuity of care for suspected patients.

Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Within ASEAN, alpha 1 antitrypsin deficiency treatment adoption is closely tied to the development of genetic testing capacity, pulmonology referral pathways, and rare disease policy maturity, with large differences between advanced urban hospitals and resource-limited settings. The GCC is positioned to advance case identification through investments in genomic medicine, specialist respiratory centers, premarital and family-based screening models where clinically appropriate, while ensuring that long-term treatment pathways align with national reimbursement structures and infusion service readiness. The European Union provides a strong environment for harmonized rare disease initiatives, cross-country clinical expertise, pharmacovigilance, and evidence-based standards, although national-level reimbursement and implementation still influence patient access. BRICS countries represent a diverse group in which large COPD populations, expanding molecular diagnostics, and growing specialty care capacity can support improved detection, but affordability, geographic access, and care coordination remain critical considerations. G7 countries generally show stronger availability of specialist care, genetic confirmation, clinical guidelines, patient advocacy, and advanced therapeutics infrastructure, making them important environments for real-world evidence and next-generation treatment evaluation. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where military and civilian health systems can benefit from standardized respiratory screening protocols, occupational exposure assessment, smoking cessation programs, and coordinated management of chronic lung disease associated with hereditary risk.

Country Insights Across Major Healthcare Markets

The United States has one of the most developed alpha 1 antitrypsin deficiency care ecosystems, with broad specialist awareness, confirmatory laboratory testing, augmentation therapy pathways, and patient support infrastructure, yet many individuals with COPD or liver disease remain undiagnosed. Canada benefits from public healthcare coordination and respiratory specialty networks, while geographic dispersion creates a need for telehealth-enabled monitoring and equitable infusion access. Mexico and Brazil face opportunities to improve detection through COPD clinics, liver disease programs, and family screening, but access to specialized diagnostics and long-term therapy can vary by region and payer structure. The United Kingdom integrates rare disease expertise with respiratory and hepatology services, supporting structured diagnosis and long-term monitoring, while Germany and France have strong clinical research capacity, specialty networks, and guideline-driven care environments. Russia, Italy, and Spain reflect varying combinations of specialist access, regional healthcare organization, and awareness initiatives, making consistent diagnostic pathways essential for timely identification. China and India have large respiratory disease burdens and expanding genetic testing capabilities, creating significant potential for improved case-finding among patients with unexplained COPD, bronchiectasis, or liver abnormalities, though broad access and clinician awareness remain uneven. Japan, Australia, and South Korea show advanced diagnostic infrastructure and specialist care capacity, with opportunities to strengthen early testing algorithms, family screening, liver surveillance, and real-world evidence collection to guide appropriate treatment selection.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize earlier diagnosis by supporting guideline-aligned testing among patients with COPD, emphysema at a young age, basilar emphysema, unexplained bronchiectasis, chronic liver disease, panniculitis, and family history of alpha 1 antitrypsin deficiency. Care models should integrate pulmonology, hepatology, genetics, primary care, infusion services, and patient education to reduce fragmentation and support lifelong monitoring. Stakeholders should invest in evidence generation that evaluates clinical outcomes, treatment adherence, quality of life, lung function trajectories, exacerbation patterns, liver-related progression, and the real-world impact of home-based care. Diagnostic strategies should combine serum alpha 1 antitrypsin measurement with phenotyping or genotyping to avoid missed cases caused by acute-phase elevation or variant complexity. Access planning should address payer criteria, infusion logistics, rural reach, specialty referral delays, and patient burden. Digital tools, including AI-enabled case-finding, should be clinically validated and implemented with privacy, interoperability, and health equity safeguards. For emerging therapies, leaders should prepare education, biomarker strategies, trial diversity plans, and post-authorization evidence frameworks that reflect the dual lung and liver burden of the disease.

Research Methodology

This executive summary is built on a structured secondary research methodology focused on verified clinical, regulatory, epidemiological, and scientific sources. The approach emphasizes peer-reviewed literature on alpha 1 antitrypsin deficiency genetics, diagnosis, pulmonary and hepatic manifestations, augmentation therapy, monitoring standards, and investigational treatment modalities. It also incorporates publicly available guidance from recognized clinical societies, rare disease authorities, public health agencies, and regulatory bodies, alongside evidence from registries, consensus statements, and real-world clinical studies where available. Source triangulation is used to compare diagnostic recommendations, treatment eligibility criteria, regional access patterns, and emerging technology trends across healthcare systems. The methodology intentionally excludes unsupported market sizing, estimation, share analysis, and forecasting, focusing instead on evidence-backed clinical and strategic insights. Regional, group, and country narratives are interpreted through the lenses of diagnostic infrastructure, specialist availability, reimbursement environment, rare disease policy, genetic testing maturity, and continuity-of-care capabilities.

Conclusion

Alpha 1 antitrypsin deficiency treatment is entering a more precision-driven era defined by earlier testing, multidisciplinary management, improved patient support, and scientific progress toward disease-modifying innovation. While augmentation therapy remains an established option for selected individuals with severe deficiency and emphysema, the broader treatment opportunity lies in identifying patients before irreversible lung damage advances and ensuring coordinated monitoring for both pulmonary and hepatic complications. Regional and country-level differences in diagnostic access, rare disease infrastructure, and long-term therapy delivery continue to shape patient outcomes. Artificial intelligence, real-world evidence, and genomic medicine can accelerate progress when integrated responsibly into validated clinical pathways. The most successful stakeholders will be those that align education, diagnostics, access, evidence generation, and patient-centered care to reduce underdiagnosis and improve the quality and consistency of treatment for alpha 1 antitrypsin deficiency worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Therapy Class

  • 7.1. Introduction
  • 7.2. Augmentation Therapy
  • 7.3. Gene Therapy
    • 7.3.1. AAV Vector
    • 7.3.2. Lentiviral Vector
  • 7.4. Plasma Infusion

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Delivery Mode

  • 8.1. Introduction
  • 8.2. Inhalation
  • 8.3. Intravenous

9. Alpha 1 Antitrypsin Deficiency Treatment Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Geriatrics
  • 9.4. Pediatrics

10. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Alpha 1 Antitrypsin Deficiency Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Homecare
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Alpha 1 Antitrypsin Deficiency Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Alpha 1 Antitrypsin Deficiency Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AstraZeneca PLC
  • 16.2. Baxter International Inc.
  • 16.3. Bayer AG
  • 16.4. Biogen Inc.
  • 16.5. Biotest AG
  • 16.6. Boehringer Ingelheim International GmbH
  • 16.7. CSL Behring GmbH
  • 16.8. GlaxoSmithKline plc
  • 16.9. Grifols S.A.
  • 16.10. Kamada Pharmaceuticals
  • 16.11. Takeda Pharmaceutical Company Limited
  • 16.12. Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUGMENTATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUGMENTATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUGMENTATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AAV VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AAV VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AAV VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LENTIVIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LENTIVIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LENTIVIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 154. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 161. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 168. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 196. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 210. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 245. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 249. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025